BANFF, Alberta--(BUSINESS WIRE)--Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.
BANFF, Alberta--(BUSINESS WIRE)--Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.
